Key Highlights
- Partnership to expand molecular testing across European and UK markets.
- Focus on rapid, in-house cancer diagnosis using NGS liquid biopsy panels.
- Pillar’s oncoRevealTM LBx panels offer high sensitivity with results in less than three days.
- Scalable sequencing for economic value using Illumina NextSeq™.
Source: PR Newswire
Notable Quotes
- “Access to cost-effective, easy-to-use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally.” — Dan Harma, Chief Commercial Officer at Pillar Biosciences
- “We are committed to expanding global patient access to biomarker testing, and decentralized NGS solutions are key to this strategy.” — John Longshore, Head of Scientific Affairs, Global Oncology Diagnostics at AstraZeneca
SoHC's Take
This strategic partnership between Pillar Biosciences and AstraZeneca is a significant development in cancer diagnostics, especially in the European and UK markets. The ability to offer rapid and scalable Next Generation Sequencing (NGS) liquid biopsy tumor profiling empowers local laboratories to perform complex cancer diagnostics in-house. By reducing turnaround times from weeks to just a few days, Pillar’s oncoRevealTM LBx panels not only increase efficiency but also enhance clinical decision-making. This collaboration highlights the importance of decentralized testing in improving global access to precision oncology treatments.
Heading
Key Highlights Ginkgo Bioworks releases first proprietary protein LLM, trained on exclusive datasets.Collaboration with Google Cloud enables AI-driven drug discovery tools.Open API allows researchers to access Ginkgo’s machine ...
Key Highlights Courtney Green joins QGenda as Vice President of Nurse and Staff Solutions.Brings over 20 years of clinical and operational leadership experience.Focus on optimizing ...
Key Highlights Vyne Medical® acquires Extract Systems®, a leader in data extraction solutions.Accelerates healthcare automation by integrating AI and machine learning ...
Key Highlights PatientPay integrates with Azalea Health’s API to streamline patient billing for ambulatory providers.Faster revenue capture with less than 14 days to payment, ...
Key Highlights Partnership streamlines revenue cycle management for ABA therapy providers.Flychain’s financial tools offer real-time insights, secure funding, and automation.Raven ...
Key Highlights Nura Bio closes $140M Series A financing to support clinical development.Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success ...
